Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Risk of fracture with thiazolidinediones: disease or drugs?

Bazelier MT, Vestergaard P, Gallagher AM, van Staa TP, Cooper C, Leufkens HG, de Vries F.

Calcif Tissue Int. 2012 Jun;90(6):450-7. doi: 10.1007/s00223-012-9591-8. Epub 2012 Apr 10.

2.

Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?

Bazelier MT, Gallagher AM, van Staa TP, Cooper C, Leufkens HG, Vestergaard P, de Vries F.

Pharmacoepidemiol Drug Saf. 2012 May;21(5):507-14. doi: 10.1002/pds.3234. Epub 2012 Mar 6.

PMID:
22392882
3.

Use of thiazolidinediones and risk of bladder cancer: disease or drugs?

Bazelier MT, de Vries F, Vestergaard P, Leufkens HG, De Bruin ML.

Curr Drug Saf. 2013 Nov;8(5):364-70.

PMID:
24215315
4.

Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11.

PMID:
24029780
5.

Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.

Schwartz AV, Chen H, Ambrosius WT, Sood A, Josse RG, Bonds DE, Schnall AM, Vittinghoff E, Bauer DC, Banerji MA, Cohen RM, Hamilton BP, Isakova T, Sellmeyer DE, Simmons DL, Shibli-Rahhal A, Williamson JD, Margolis KL.

J Clin Endocrinol Metab. 2015 Nov;100(11):4059-66. doi: 10.1210/jc.2015-1215. Epub 2015 Aug 25.

PMID:
26305617
6.

Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.

Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, Joseph G, Yu S.

Clin Drug Investig. 2013 Sep;33(9):621-31. doi: 10.1007/s40261-013-0106-9.

7.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894
8.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
9.

Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.

Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK.

J Clin Endocrinol Metab. 2010 Feb;95(2):592-600. doi: 10.1210/jc.2009-1385. Epub 2010 Jan 8.

10.

Use of thiazolidinediones and fracture risk.

Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR.

Arch Intern Med. 2008 Apr 28;168(8):820-5. doi: 10.1001/archinte.168.8.820.

PMID:
18443256
11.

A cohort study of thiazolidinediones and fractures in older adults with diabetes.

Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Stürmer T.

J Clin Endocrinol Metab. 2009 Aug;94(8):2792-8. doi: 10.1210/jc.2008-2157. Epub 2009 May 26.

12.

Thiazolidinediones and fractures: evidence from translating research into action for diabetes.

Bilik D, McEwen LN, Brown MB, Pomeroy NE, Kim C, Asao K, Crosson JC, Duru OK, Ferrara A, Hsiao VC, Karter AJ, Lee PG, Marrero DG, Selby JV, Subramanian U, Herman WH.

J Clin Endocrinol Metab. 2010 Oct;95(10):4560-5. doi: 10.1210/jc.2009-2638. Epub 2010 Jul 14.

13.

Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.

Lin HC, Hsu YT, Kachingwe BH, Hsu CY, Uang YS, Wang LH.

J Clin Pharm Ther. 2014 Aug;39(4):354-60. doi: 10.1111/jcpt.12151. Epub 2014 Mar 24.

PMID:
24661226
14.

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD.

J Natl Cancer Inst. 2012 Sep 19;104(18):1411-21. Epub 2012 Aug 9.

15.

Risk of fracture with thiazolidinediones: an individual patient data meta-analysis.

Bazelier MT, de Vries F, Vestergaard P, Herings RM, Gallagher AM, Leufkens HG, van Staa TP.

Front Endocrinol (Lausanne). 2013 Feb 26;4:11. doi: 10.3389/fendo.2013.00011. eCollection 2013.

16.

Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.

Stockl KM, Le L, Zhang S, Harada AS.

Pharmacoepidemiol Drug Saf. 2009 Feb;18(2):166-74. doi: 10.1002/pds.1700.

PMID:
19109802
17.

Thiazolidinediones and fractures in men and women.

Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM.

Arch Intern Med. 2009 Aug 10;169(15):1395-402. doi: 10.1001/archinternmed.2009.214.

PMID:
19667303
18.

Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.

Driessen JH, van Onzenoort HA, Henry RM, Lalmohamed A, van den Bergh JP, Neef C, Leufkens HG, de Vries F.

Bone. 2014 Nov;68:124-30. doi: 10.1016/j.bone.2014.07.030. Epub 2014 Aug 2.

PMID:
25093264
19.

Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.

Driessen JH, Henry RM, van Onzenoort HA, Lalmohamed A, Burden AM, Prieto-Alhambra D, Neef C, Leufkens HG, de Vries F.

Calcif Tissue Int. 2015 Aug;97(2):104-12. doi: 10.1007/s00223-015-9993-5. Epub 2015 Apr 17.

20.

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.

Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay RS, Reed C, Donnan PT, Guthrie B, Leese GP, McKnight J, Pearson DW, Pearson E, Petrie JR, Philip S, Sattar N, Sullivan FM, McKeigue P; Scottish Diabetes Research Network Epidemiology Group.

Diabetologia. 2012 Nov;55(11):2929-37. doi: 10.1007/s00125-012-2668-0. Epub 2012 Sep 4.

Items per page

Supplemental Content

Write to the Help Desk